N,N'-Diacetylhydrazine, also known as 1,2-diacetylhydrazine, is a white crystalline solid that is commonly used as a precursor in the synthesis of various chemical compounds. Its synthesis involves the reaction of hydrazine with acetic anhydride. The compound exhibits interesting biological activities, such as antitumor and anti-inflammatory effects, making it a subject of extensive research in the field of medicinal chemistry. Its potential applications in pharmaceuticals and agrochemicals are also being explored. The molecule's ability to form metal complexes has garnered attention in the field of coordination chemistry, leading to studies on its complexation behavior with different metal ions.'
| ID Source | ID |
|---|---|
| PubMed CID | 72884 |
| CHEMBL ID | 3091852 |
| CHEBI ID | 80616 |
| SCHEMBL ID | 606948 |
| SCHEMBL ID | 23224226 |
| MeSH ID | M0124787 |
| Synonym |
|---|
| 1.2-diacetylhydrazine |
| acetic acid, 2-acetylhydrazide |
| nsc 42939 |
| hydrazine,2-diacetyl- |
| nsc42939 |
| 1,2-diacetylhydrazine |
| nsc-42939 |
| n,n'-diacetylhydrazine |
| diacetyl hydrazine |
| einecs 221-576-1 |
| sym-diacetylhydrazine |
| diacetylahydrazine |
| hydrazine, 1,2-diacetyl- |
| diacetylhydrazine |
| n'-acetylacetohydrazide |
| 3148-73-0 |
| 1,2-diacetylhydrazine, 98% |
| D2796 |
| NCGC00248525-01 |
| n'-acetyl-acetic acid hydrazide |
| NCGC00257653-01 |
| dtxsid7020390 , |
| cas-3148-73-0 |
| dtxcid10390 |
| tox21_200099 |
| A820875 |
| unii-ymr3zf0q4m |
| ymr3zf0q4m , |
| ec 221-576-1 |
| FT-0606330 |
| AKOS015900792 |
| SCHEMBL606948 |
| CHEMBL3091852 |
| chebi:80616 , |
| diacetylhydrazide |
| n'-acetylacetohydrazide # |
| mfcd00008673 |
| AS-57968 |
| J-018442 |
| Q27149664 |
| D87230 |
| SCHEMBL23224226 |
| SB86069 |
| n,n inverted exclamation mark -diacetylhydrazine |
| SY048493 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " This pharmacokinetic analysis, however, also shows that the apparent plasma half-life of acetylhydrazine is about five times longer than the plasma half-life of isoniazid, and thus repeated doses of isoniazid should lead to an accumulation of acetylhydrazine in the slowest acetylators in which the plasma half-life of acetylhydrazine is 20-plus hr." | ( Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. Lauterburg, BH; Mitchell, JR; Smith, CV; Todd, EL, 1985) | 0.27 |
| Class | Description |
|---|---|
| carbohydrazide | A hydrazide consisting of hydrazine carrying one or more carboacyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1059231 | Antitubercular activity against Mycobacterium tuberculosis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds. |
| AID1059234 | Lipophilicity, log P of the compound | 2013 | European journal of medicinal chemistry, , Volume: 70 | Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||